China Reform Health Management and Services Group Valuation

Is 000503 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 000503 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 000503's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 000503's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 000503?

Key metric: As 000503 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 000503. This is calculated by dividing 000503's market cap by their current revenue.
What is 000503's PS Ratio?
PS Ratio	36x
Sales	CN¥369.39m
Market Cap	CN¥13.29b

000503 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	33.1x
Enterprise Value/EBITDA	-140.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 000503's PS Ratio compare to its peers?

The above table shows the PS ratio for 000503 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.5x
600211 Tibet Rhodiola Pharmaceutical Holding	4x	20.5%	CN¥11.7b
301015 Qingdao Baheal Medical	1.7x	10.2%	CN¥13.9b
000028 China National Accord Medicines	0.2x	5.7%	CN¥15.3b
000950 C.Q. Pharmaceutical Holding	0.1x	10.1%	CN¥9.6b
000503 China Reform Health Management and Services Group	36x	n/a	CN¥13.3b

Price-To-Sales vs Peers: 000503 is expensive based on its Price-To-Sales Ratio (36x) compared to the peer average (1.5x).

Price to Sales Ratio vs Industry

How does 000503's PS Ratio compare vs other companies in the CN Healthcare Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap
601607 Shanghai Pharmaceuticals Holding	0.3x	9.5%	US$9.84b
600998 Jointown Pharmaceutical Group	0.2x	8.0%	US$3.55b
000028 China National Accord Medicines	0.2x	5.7%	US$2.11b
000950 C.Q. Pharmaceutical Holding	0.1x	10.1%	US$1.32b

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 000503 is expensive based on its Price-To-Sales Ratio (36x) compared to the CN Healthcare industry average (1.8x).

Price to Sales Ratio vs Fair Ratio

What is 000503's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

000503 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	36x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 000503's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shenzhen Lifotronic Technology

CN¥6.7b

Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.

688389

CN¥15.53

-5.8%

-34.9%

Chison Medical Technologies

CN¥2.7b

Manufactures and sells diagnostic ultrasound systems in China and internationally.

688358

CN¥24.06

-8.2%

-44.8%

Winner Medical

CN¥19.7b

Engages in the research and development, manufacture, and marketing of cotton-based medical dressings and medical disposables, and consumer products in China.

300888

CN¥33.90

5.4%

-14.7%